Cargando…
A randomized single and multiple ascending dose study in healthy volunteers of LTI‐291, a centrally penetrant glucocerebrosidase activator
AIMS: A mutation in the GBA1 gene is the most common genetic risk factor for developing Parkinson's disease. GBA1 encodes the lysosomal enzyme glucosylceramidase beta (glucocerebrosidase, GCase) and mutations decrease enzyme activity. LTI‐291 is an allosteric modulator of GCase, enhancing its a...
Autores principales: | den Heijer, Jonas M., Kruithof, Annelieke C., van Amerongen, Guido, de Kam, Marieke L., Thijssen, Eva, Grievink, Hendrika W., Moerland, Matthijs, Walker, Mike, Been, Kees, Skerlj, Renato, Justman, Craig, Dudgeon, Lindsay, Lansbury, Peter, Cullen, Valerie C., Hilt, Dana C., Groeneveld, Geert Jan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451761/ https://www.ncbi.nlm.nih.gov/pubmed/33576113 http://dx.doi.org/10.1111/bcp.14772 |
Ejemplares similares
-
False negatives in GBA1 sequencing due to polymerase dependent allelic imbalance
por: den Heijer, Jonas M., et al.
Publicado: (2021) -
Instrumentation needs for LTI
por: Meddahi, Malika
Publicado: (2001) -
Good Clinical Trials by removing defensive interpretation of Good Clinical Practice guidelines
por: den Heijer, Jonas M., et al.
Publicado: (2021) -
Glucocerebrosidase: Functions in and Beyond the Lysosome
por: Boer, Daphne E.C., et al.
Publicado: (2020) -
Post-mortem of the LTI project seen from AB/BDI
por: Jensen, L
Publicado: (2004)